Taysha Gene Therapies (TSHA)
NASDAQ:TSHA
Top Page
Taysha Gene Therapies
(NASDAQ:TSHA)
Select Model
Select Model
Rating:49Neutral
Price Target:
$4.00
▼(-3.15% Downside)
Action:ReiteratedDate:03/25/26
The score is weighed down primarily by weak financial performance driven by persistent large losses and substantial cash burn. Technicals also remain bearish with the stock below key moving averages and negative momentum. These are partially offset by a constructive earnings-call backdrop highlighting significant clinical/regulatory progress and a cash runway projected into 2028.
Positive Factors
Regulatory and clinical momentum
Breakthrough designation plus written FDA alignment on trial designs, CMC comparability and PPQ materially reduce regulatory uncertainty and enable pooling of datasets to support a BLA. This structural de‑risking accelerates potential approval pathways and supports sustained program value over the next 2–6 months.
Negative Factors
Persistent heavy cash burn
Multi-year negative operating and free cash flows indicate ongoing high cash consumption tied to clinical and manufacturing activity. Unless burn meaningfully declines, the company will remain dependent on external financing, raising dilution and execution risk that persist across multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory and clinical momentum
Breakthrough designation plus written FDA alignment on trial designs, CMC comparability and PPQ materially reduce regulatory uncertainty and enable pooling of datasets to support a BLA. This structural de‑risking accelerates potential approval pathways and supports sustained program value over the next 2–6 months.
Read all positive factors
Taysha Gene Therapies (TSHA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.30B
Dividend YieldN/A
Average Volume (3M)2.59M
Price to Earnings (P/E)―
Beta (1Y)2.62
Revenue Growth-36.36%
EPS Growth-945.72%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding287,269,900
10 Day Avg. Volume3,193,642
30 Day Avg. Volume2,588,422
Financial Highlights & Ratios
PEG Ratio2.90
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue74.86
Enterprise Value/Gross Profit79.62
Enterprise Value/Ebitda-6.76
Forecast
1Y Price Target
$12.11Price Target Upside193.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.44
Revenue Forecast (FY)$4.46M
Taysha Gene Therapies Business Overview & Revenue Model
Company Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for th...
How the Company Makes Money
As a clinical-stage gene therapy company without approved products, Taysha has historically generated little to no recurring revenue from product sales; its operations have primarily been funded through capital raising and, where applicable, other...
Taysha Gene Therapies Earnings Call Summary
Earnings Call Date:Mar 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 20, 2026
Earnings Call Sentiment Positive
The call emphasized substantial clinical and regulatory progress — compelling Part A efficacy signals, initiation of the pivotal trial, FDA Breakthrough designation, written FDA alignments on trial designs and CMC comparability, and a clear commercial readiness plan — supported by a solid cash position into 2028. These positives are tempered by rising R&D and G&A expenses, a larger net loss in 2025, small sample sizes in key pediatric safety cohorts, and contingent regulatory timing that could require longer follow-up. On balance, the forward clinical and regulatory momentum materially outweighs the financial and operational risks discussed.Positive Updates
Compelling Clinical Efficacy Signals in REVEAL Part A
REVEAL Part A reported a 100% response rate among the 10 treated patients across low- and high-dose cohorts, with an 83% response rate at six months in the high-dose group (5 of 6). Management reported an average of ~19 developmental milestone gains per patient from a 32-milestone set, sustained and deepening over time.
Negative Updates
Rising Operating Expenses
Research and development expenses increased to $86.4 million in 2025 from $66.0 million in 2024 — a $20.4 million increase (approximately +30.9%), driven by higher headcount, clinical trial and GMP expenses. General and administrative expenses rose to $33.9 million from $29.0 million — a $4.9 million increase (approximately +16.9%).
Read all updates
Q4-2025 Updates
Positive
Negative
Compelling Clinical Efficacy Signals in REVEAL Part A
REVEAL Part A reported a 100% response rate among the 10 treated patients across low- and high-dose cohorts, with an 83% response rate at six months in the high-dose group (5 of 6). Management reported an average of ~19 developmental milestone gains per patient from a 32-milestone set, sustained and deepening over time.
Read all positive updates
Company Guidance
On the March 19, 2026 call (full-year 2025 results) Taysha reiterated regulatory and development guidance: REVEAL pivotal was initiated in 2025 with multiple patients dosed and dosing expected to complete in 2026, a six‑month interim analysis (FDA‑aligned) is planned and could support a BLA filing (alternatively a 12‑month or rolling approach remains possible); ASPIRE will enroll three females aged 2 to <4 years, use a brain‑volume‑scaled high dose (equivalent to 1e15 total vector genomes), requires a minimum of 3 months’ safety data for the BLA, and is on track to complete dosing in 2026; the FDA agreed to pool data from REVEAL Part A/Phase 1/2, the pivotal and ASPIRE given CMC comparability, endorsed the PPQ/process validation and stability/potency plan (PPQ lots to initiate in 2026 and complete by year‑end), and the program holds Breakthrough Therapy designation. Clinical metrics highlighted: Part A earlier showed a 100% response rate in 10 treated patients, an 83% response at six months (5/6 high‑dose patients), ~19 average milestone gains per patient across 32 developmental milestones, a planned pivotal cohort of 15 patients aged 6 to <52 testing against a ~6.3–6.7% spontaneous‑improvement benchmark (spontaneous gains up to ~85% at ages 1–5); Q2 2026 will report comprehensive data on all 12 Part A pediatric patients with ≥12‑month follow‑up. Financial guidance/metrics: FY2025 R&D $86.4M, G&A $33.9M, net loss $109.0M ($0.34/sh) vs. $89.3M ($0.36) in FY2024, cash & equivalents $319.8M as of 12/31/2025 (plus $50M gross ATM raised in Q4) and management expects cash to fund operations into 2028; estimated addressable Rett population ~15,000–20,000 (U.S. ~6,000–9,000).Taysha Gene Therapies Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.77M | 8.33M | 15.45M | 2.50M | 0.00 |
| Gross Profit | 8.63M | 8.33M | 15.45M | 15.00K | 0.00 |
| EBITDA | -109.35M | -87.95M | -105.20M | -159.73M | -172.60M |
| Net Income | -109.00M | -89.30M | -111.57M | -166.01M | -174.52M |
Balance Sheet | |||||
| Total Assets | 343.32M | 160.36M | 172.73M | 126.28M | 213.96M |
| Cash, Cash Equivalents and Short-Term Investments | 319.77M | 139.04M | 143.94M | 87.88M | 149.10M |
| Total Debt | 18.17M | 63.18M | 61.11M | 59.93M | 63.09M |
| Total Liabilities | 96.38M | 88.84M | 97.79M | 125.33M | 118.57M |
| Stockholders Equity | 246.94M | 71.53M | 74.94M | 949.00K | 95.38M |
Cash Flow | |||||
| Free Cash Flow | -93.83M | -81.60M | -80.39M | -113.26M | -138.60M |
| Operating Cash Flow | -93.09M | -81.22M | -73.02M | -88.39M | -117.04M |
| Investing Cash Flow | -604.00K | -363.00K | -7.35M | -24.93M | -21.55M |
| Financing Cash Flow | 274.59M | 76.68M | 136.39M | 52.10M | 39.08M |
Taysha Gene Therapies Technical Analysis
Negative
4.13
Price Trends
4.63
Negative
4.76
Negative
3.97
Positive
Market Momentum
-0.08
Positive
36.43
Neutral
29.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSHA, the sentiment is Negative. The current price of 4.13 is below the 20-day moving average (MA) of 4.52, below the 50-day MA of 4.63, and above the 200-day MA of 3.97, indicating a neutral trend. The MACD of -0.08 indicates Positive momentum. The RSI at 36.43 is Neutral, neither overbought nor oversold. The STOCH value of 29.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSHA.
Taysha Gene Therapies Risk Analysis
Taysha Gene Therapies disclosed 83 risk factors in its most recent earnings report. Taysha Gene Therapies reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Taysha Gene Therapies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $1.76B | -5.25 | -43.17% | ― | -16.50% | 33.02% | |
53 Neutral | $761.61M | -6.95 | -100.29% | ― | 5459.66% | -59.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.35B | -8.83 | -57.61% | ― | -4.44% | 63.58% | |
50 Neutral | $646.38M | -2.57 | -178.61% | ― | 647.13% | 26.79% | |
49 Neutral | $1.30B | -16.13 | -56.64% | ― | -36.36% | -945.72% | |
46 Neutral | $832.62M | -4.22 | -141.99% | ― | ― | 31.16% |
* Healthcare Sector Average
TSHA
Taysha Gene Therapies
4.13
2.36
133.33%
RLAY
Relay Therapeutics
9.44
6.48
218.92%
IMNM
Immunome
20.21
13.26
190.79%
SPRY
ARS Pharmaceuticals
7.54
-5.61
-42.66%
SANA
Sana Biotechnology
2.92
0.77
35.81%
PRME
Prime Medicine, Inc.
3.52
1.57
80.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.